EP4100402A1 - Modulateurs de kv3 - Google Patents

Modulateurs de kv3

Info

Publication number
EP4100402A1
EP4100402A1 EP20705484.2A EP20705484A EP4100402A1 EP 4100402 A1 EP4100402 A1 EP 4100402A1 EP 20705484 A EP20705484 A EP 20705484A EP 4100402 A1 EP4100402 A1 EP 4100402A1
Authority
EP
European Patent Office
Prior art keywords
disorders
benzofuran
compound
dione
imidazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20705484.2A
Other languages
German (de)
English (en)
Inventor
Giuseppe Alvaro
Agostino Marasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of EP4100402A1 publication Critical patent/EP4100402A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'invention concerne un composé de formule (I) et des aspects associés.
EP20705484.2A 2020-02-06 2020-02-06 Modulateurs de kv3 Pending EP4100402A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Publications (1)

Publication Number Publication Date
EP4100402A1 true EP4100402A1 (fr) 2022-12-14

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20705484.2A Pending EP4100402A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Country Status (11)

Country Link
EP (1) EP4100402A1 (fr)
JP (1) JP2023523501A (fr)
KR (1) KR20220139923A (fr)
CN (1) CN115066424A (fr)
AU (1) AU2020427632A1 (fr)
BR (1) BR112022013339A2 (fr)
CA (1) CA3169057A1 (fr)
CL (1) CL2022002081A1 (fr)
IL (1) IL295027A (fr)
MX (1) MX2022009702A (fr)
WO (1) WO2021156584A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019970B8 (ru) 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
BR112013013914B1 (pt) 2010-12-06 2021-10-26 Autifony Therapeutics Limited Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos
WO2012168710A1 (fr) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
KR20140098850A (ko) * 2011-12-06 2014-08-08 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
EP2852589B1 (fr) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles en tant qu'inhibiteurs de kv3
WO2013182851A1 (fr) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
EP3853216A4 (fr) 2018-09-21 2022-08-10 Bionomics Limited Composés substitués par pyridinyle et leurs utilisations
BR112021006940A2 (pt) * 2018-10-16 2021-07-13 Autifony Therapeutics Limited compostos
US20220112176A1 (en) 2019-03-25 2022-04-14 Bionomics Limited Substituted-n-heteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
KR20220139923A (ko) 2022-10-17
AU2020427632A1 (en) 2022-08-18
WO2021156584A1 (fr) 2021-08-12
MX2022009702A (es) 2022-09-07
CA3169057A1 (fr) 2021-08-12
CL2022002081A1 (es) 2023-05-26
CN115066424A (zh) 2022-09-16
IL295027A (en) 2022-09-01
BR112022013339A2 (pt) 2022-09-13
JP2023523501A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
US11541052B2 (en) Compounds
US11180461B2 (en) Triazoles as Kv3 inhibitors
US9193704B2 (en) Hydantoin derivatives as KV3 inhibitors
EP3490977B1 (fr) Dérivés cyclobutane comme modulateurs des canaux potassiques voltage-dépendants
EP3390394B1 (fr) Hydantoïnes utilisées en tant que modulateurs de canaux kv3
CA2856654C (fr) Derives d'hydantoine utiles comme inhibiteurs de kv3
AU2019360017A1 (en) Novel compounds
WO2018109484A1 (fr) Modulateurs d'hydantoïne de canaux kv3
WO2013182850A1 (fr) Modulateurs des canaux potassium kv3 à base de dérivés d'isobenzofuran- 5-yl-oxy(hétéro)aryl-imidazolidine-2,4-dione pour traiter les troubles du snc
AU2020427632A1 (en) Kv3 modulators
US20210276985A1 (en) Novel compounds
AU2022327657A1 (en) Potassium channel modulators

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084477

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230911